Non-metastatic high-risk prostate cancer patients with biochemical relapse only after local treatment. A prospective randomized phase III study comparing hormonal therapy +/--docetaxel.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Jun 2013
At a glance
- Drugs Docetaxel (Primary) ; Triptorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 04 Jun 2013 Quality-of-life results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2011 Final results for PSA-progression-free survival presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History